GlassScriptPhysician profile
Vernon Hattori
NPI 1568468684
$7,277.58
in general payments reported to CMS, 2019-2025
35 companies · $824 in 2025
The $824 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,099 · 2020: $779 · 2021: $1,297 · 2022: $925 · 2023: $1,283 · 2024: $1,071 · 2025: $824.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,158 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,158.20 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,134.32 | 2019-2025 | |
| Pfizer INC. | $715.49 | 2019-2025 | |
| Amgen INC. | $628.63 | 2019-2023 | Repatha |
| Novo Nordisk INC | $515.40 | 2019-2025 | Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $487.45 | 2023-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $340.68 | 2023-2025 | Verquvo, Winrevair |
| Janssen Pharmaceuticals, INC | $314.00 | 2019-2022 | |
| Esperion Therapeutics, INC. | $313.38 | 2020-2025 | Nexletol |
| Abbott Laboratories | $274.72 | 2019-2022 | |
| Scpharmaceuticals INC. | $153.37 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $146.27 | 2022-2025 | Eliquis, Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $142.55 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $132.86 | 2019-2025 | Wainua, Farxiga, Brilinta |
| Shockwave Medical, INC | $122.41 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Akcea Therapeutics, INC. | $112.06 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $109.77 | 2022-2023 | Amvuttra |
| Gilead Sciences, INC. | $81.66 | 2019 | |
| Kestra Medical Technology Services, INC. | $75.89 | 2025 | Assure Wcd |
| Sanofi-Aventis U.S. LLC | $52.90 | 2019 | |
| Edwards Lifesciences Corporation | $48.11 | 2021 | |
| Angiodynamics, INC. | $43.89 | 2025 | Alphavac |
| Astellas Pharma US INC | $41.04 | 2020-2021 | |
| Impulse Dynamics (USA) INC. | $39.19 | 2023 | Optimizer |
| Ionis Pharmaceuticals, INC. | $37.90 | 2025 | Tryngolza |
| Abiomed | $34.41 | 2020 | |
| Irhythm Technologies, INC. | $24.09 | 2022 | |
| Preventice Services, LLC | $21.98 | 2021 | |
| Glaxosmithkline, LLC. | $20.57 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $20.53 | 2023 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $18.97 | 2021 | |
| Cardiovascular Systems INC. | $16.74 | 2019-2020 | |
| Bardy Diagnostics, INC. | $16.31 | 2020 | |
| Medtronic, INC. | $16.28 | 2021 | |
| Medtronic Vascular, INC. | $12.39 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vernon Hattori listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.